Dashboard
PDUFA
PDUFA History
Dilution Watch
Downside Radar
Missed Milestones
Earnings
Big Movers
Blog
🎤 Upcoming Biotech Conferences
Loading conferences...
Free to browse, no account needed
Track cancer catalysts with approval-probability scores and free alerts.
Oncology Biotech Pipeline: Cancer Drugs in Clinical Development
Every cancer program BioRadar tracks across 303 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 3912 cancer drug programs across 303 public companies, with 3 upcoming FDA decisions in this area. The most active companies by program count are IBRX, MRK, SNDX, BNTX, KPTI.
3912Drug programs
303Companies
885In Phase 3
3Upcoming FDA dates
Upcoming FDA decisions in Oncology (Cancer)
Companies with cancer programs
IBRX
98 programs
MRK
85 programs
SNDX
81 programs
BNTX
71 programs
KPTI
70 programs
GMAB
69 programs
BMY
67 programs
NKTR
61 programs
ONC
59 programs
ABBV
58 programs
AZN
54 programs
RCUS
54 programs
AGEN
53 programs
IOVA
52 programs
MGNX
52 programs
CLDX
51 programs
GILD
49 programs
JAZZ
49 programs
NVS
47 programs
IMTX
45 programs
PFE
45 programs
VSTM
44 programs
SMMT
43 programs
EXEL
41 programs
LLY
40 programs
PBYI
40 programs
ZLAB
40 programs
INCY
39 programs
ADCT
38 programs
ONCY
37 programs
RVMD
37 programs
AAPG
32 programs
ADAG
32 programs
HCM
32 programs
HALO
31 programs
REGN
31 programs
FATE
29 programs
MYGN
29 programs
TCRT
29 programs
XNCR
29 programs
CHRS
28 programs
LEGN
28 programs
IMCR
27 programs
TCRX
27 programs
AMGN
26 programs
KURA
25 programs
ACHV
24 programs
ALXO
24 programs
TGTX
24 programs
IBO
23 programs
ACTU
22 programs
IDYA
22 programs
INBX
22 programs
NCNA
22 programs
CELC
21 programs
REPL
21 programs
TLX
21 programs
TPST
21 programs
ARVN
20 programs
IPHA
20 programs
ANL
19 programs
BLRX
19 programs
CRDF
19 programs
GSK
19 programs
IMMP
19 programs
IMNN
19 programs
RNA
19 programs
TAK
19 programs
APVO
18 programs
CORT
18 programs
NXTC
18 programs
ORIC
18 programs
CRIS
17 programs
ERAS
17 programs
INO
17 programs
JNJ
17 programs
LNTH
17 programs
NUVB
17 programs
URGN
17 programs
ZYME
17 programs
SBFM
16 programs
AIM
15 programs
EIKN
15 programs
MRKR
15 programs
ZNTL
15 programs
CADL
14 programs
GERN
14 programs
LGND
14 programs
ATNM
13 programs
CMPS
13 programs
CMPX
13 programs
COGT
13 programs
LSTA
13 programs
MEDP
13 programs
RIGL
13 programs
SNY
13 programs
ACOG
12 programs
ADPT
12 programs
CGEM
12 programs
CNTX
12 programs
GNPX
12 programs
OLMA
12 programs
PRLD
12 programs
SLS
12 programs
STRO
12 programs
TKNO
12 programs
APRE
11 programs
BCTX
11 programs
CTMX
11 programs
ELVN
11 programs
PBH
11 programs
VERU
11 programs
CELU
10 programs
CRVS
10 programs
GALT
10 programs
GNLX
10 programs
KZIA
10 programs
LTRN
10 programs
MBIO
10 programs
TRAW
10 programs
ALLR
9 programs
ARTV
9 programs
CATX
9 programs
CGEN
9 programs
CLRB
9 programs
IMRX
9 programs
IQV
9 programs
KYNB
9 programs
LYEL
9 programs
MOLN
9 programs
NRIX
9 programs
NUVL
9 programs
TNGX
9 programs
TVRD
9 programs
AVBP
8 programs
BYSI
8 programs
CAH
8 programs
CCCC
8 programs
ICLR
8 programs
TOVX
8 programs
ACRS
7 programs
AUTL
7 programs
CRBP
7 programs
MAIA
7 programs
OKUR
7 programs
RNAC
7 programs
STTK
7 programs
AGIO
6 programs
APLM
6 programs
ASND
6 programs
ATRA
6 programs
BOLD
6 programs
BOLT
6 programs
CGON
6 programs
CLLS
6 programs
INTS
6 programs
KRYS
6 programs
MBRX
6 programs
PGEN
6 programs
RNAZ
6 programs
TYRA
6 programs
VIR
6 programs
XLO
6 programs
BCAX
5 programs
BHVN
5 programs
BTAI
5 programs
CRBU
5 programs
EVAX
5 programs
FTH
5 programs
GENB
5 programs
JANX
5 programs
NERV
5 programs
PBLS
5 programs
VRCA
5 programs
ACET
4 programs
ALLO
4 programs
BLSM
4 programs
CRSP
4 programs
CVM
4 programs
GLSI
4 programs
GOSS
4 programs
PTCT
4 programs
PYXS
4 programs
RADX
4 programs
RXRX
4 programs
SLN
4 programs
TLSA
4 programs
XBIT
4 programs
ACRV
3 programs
ANIX
3 programs
APGE
3 programs
ARGX
3 programs
ATOS
3 programs
AURA
3 programs
BDTX
3 programs
BKHA
3 programs
BTTC
3 programs
CANF
3 programs
CUE
3 programs
DTIL
3 programs
EBS
3 programs
ELTX
3 programs
ENGN
3 programs
FHTX
3 programs
GLUE
3 programs
HOWL
3 programs
HRTX
3 programs
IRLA
3 programs
LXRX
3 programs
MCRB
3 programs
MNPR
3 programs
NBTX
3 programs
NVCT
3 programs
OGN
3 programs
OPK
3 programs
PCSA
3 programs
RDHL
3 programs
RNXT
3 programs
SNGX
3 programs
TEVA
3 programs
TIL
3 programs
VOR
3 programs
XCUR
3 programs
XFOR
3 programs
AKTS
2 programs
ALDX
2 programs
ALNY
2 programs
ALVO
2 programs
ARCT
2 programs
BCRX
2 programs
BEAM
2 programs
BFRI
2 programs
CYTK
2 programs
DMRA
2 programs
DRUG
2 programs
ENLV
2 programs
GDTC
2 programs
GOVX
2 programs
HCWB
2 programs
HURA
2 programs
IBIO
2 programs
IMMX
2 programs
INAB
2 programs
INDP
2 programs
KAPA
2 programs
KYMR
2 programs
LONA
2 programs
MESO
2 programs
MREO
2 programs
NGNE
2 programs
PLRX
2 programs
PMVP
2 programs
QGEN
2 programs
RDY
2 programs
RLMD
2 programs
RZLT
2 programs
SANA
2 programs
SRRK
2 programs
TARA
2 programs
XBIO
2 programs
ABUS
1 program
ABVX
1 program
AMRX
1 program
AVTX
1 program
BCYC
1 program
BHC
1 program
BMEA
1 program
BNTC
1 program
CBIO
1 program
CTOR
1 program
CTXR
1 program
ENTX
1 program
EOCN
1 program
ESLA
1 program
FENC
1 program
FMS
1 program
GRFS
1 program
IAM
1 program
IFRX
1 program
IMDX
1 program
IMNM
1 program
IMUX
1 program
INKT
1 program
INMB
1 program
MGTX
1 program
MNKD
1 program
OBX
1 program
OSTX
1 program
PDSB
1 program
PHIO
1 program
PPBT
1 program
PRAX
1 program
PRGO
1 program
QNTM
1 program
QUCY
1 program
RGEN
1 program
RLAY
1 program
SGMT
1 program
SNTI
1 program
TELO
1 program
VTRS
1 program
VTVT
1 program
WHWK
1 program
Phase 3 oncology (cancer) programs (885)
| Ticker | Drug | Indication |
|---|---|---|
| AAPG | Bosutinib | Chronic Myeloid Leukemia |
| AAPG | Azacitidine Injection | Acute Myeloid Leukemia |
| AAPG | APG-2575(Lisaftoclax ) | Acute Myeloid Leukemia |
| ABBV | Venetoclax | Acute Myeloid Leukemia |
| ABBV | Azacitidine | Acute Myeloid Leukemia |
| ABBV | Pivekimab Sunirine | Acute Myeloid Leukemia |
| ABBV | Telisotuzumab Vedotin | Non Small Cell Lung Cancer |
| ABBV | Docetaxel | Non Small Cell Lung Cancer |
| ABBV | Epcoritamab | Diffuse Large B-cell Lymphoma |
| ABBV | Cytarabine | Acute Myeloid Leukemia |
| ABBV | Investigator's Choice Chemotherapy | Diffuse Large B-cell Lymphoma |
| ABBV | Fludarabine | Acute Myeloid Leukemia |
| ABBV | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia |
| ACHV | Docetaxel | Non-Small Cell Lung Cancer |
| ACHV | Custirsen | Non-Small Cell Lung Cancer |
| ACHV | Prednisone | Prostate Cancer |
| ACHV | Dexamethasone | Prostate Cancer |
| ACHV | cabazitaxel | Prostate Cancer |
| ACHV | custirsen sodium | Prostate Cancer |
| ACHV | isotonic, 0.9% sodium chloride | Castrate-Resistant Prostate Cancer |
| ACHV | TOCOSOL Paclitaxel | Breast Neoplasm |
| ACHV | Taxol | Breast Neoplasm |
| ACOG | trifluridine and tipiracil | Colorectal Neoplasms |
| ACOG | AZD3759 | Non-small Cell Lung Cancer |
| ACOG | Erlotinib | Non-small Cell Lung Cancer |
| ACOG | Gefitinib | Non-small Cell Lung Cancer |
| ADCT | Rituximab | B-cell Non Hodgkin Lymphoma |
| ADCT | Gemcitabine | Relapsed Diffuse Large B-Cell Lymphoma |
| ADCT | Oxaliplatin | Relapsed Diffuse Large B-Cell Lymphoma |
| ADCT | Etoposide | B-cell Non Hodgkin Lymphoma |
| ADCT | Dexamethasone | B-cell Non Hodgkin Lymphoma |
| ADCT | CAR T-cells (TBC) | B-cell Non Hodgkin Lymphoma |
| ADCT | Ifosfamide | B-cell Non Hodgkin Lymphoma |
| ADCT | Etoposide Phosphate | B-cell Non Hodgkin Lymphoma |
| ADCT | Carboplatin | B-cell Non Hodgkin Lymphoma |
| ADCT | Odronextamab | B-cell Non Hodgkin Lymphoma |
| ADCT | Loncastuximab tesirine | B-cell Non Hodgkin Lymphoma |
| AGEN | balstilimab | Resectable MMR-deficient Solid Tumors |
| AGEN | botensilimab | Resectable MMR-deficient Solid Tumors |
| AGEN | Gemcitabine | Advanced Cancer |
Phase 2 oncology (cancer) programs (1925)
| Ticker | Drug | Indication |
|---|---|---|
| AAPG | APG-115 | Liposarcoma |
| AAPG | APG-2575 | Chronic Lymphocytic Leukemia |
| AAPG | Brentuximab Vedotin (Bv) | Cutaneous T-Cell Lymphoma/Mycosis Fungoides |
| AAPG | Carboplatin | Malignant Salivary Gland Cancer |
| AAPG | standard-dose HHT | Relapsed/Refractory Acute Myeloid Leukaemia |
| AAPG | Azacitidine | Relapsed/Refractory Acute Myeloid Leukaemia |
| AAPG | Reduced-dose HHT | Relapsed/Refractory Acute Myeloid Leukaemia |
| AAPG | HQP1351 | Chronic Myeloid Leukemia, Chronic Phase |
| AAPG | APG2575 | Chronic Lymphocytic Leukemia |
| AAPG | Gemcitabine | Advanced Pancreatic Cancer |
| AAPG | APG-1387 for Injection | Advanced Solid Tumor |
| AAPG | Nab paclitaxel | Advanced Pancreatic Cancer |
| AAPG | Toripalimab | Liposarcoma |
| AAPG | Phase 1b: APG-115+pembrolizumab | Unresectable or Metastatic Melanoma or Advanced So |
| AAPG | Ibrutinib | Chronic Lymphocytic Leukemia |
| AAPG | Hydroxyurea or Interferon-based therapy | Chronic Myeloid Leukemia, Chronic Phase |
| AAPG | Homoharringtonine | Chronic Myeloid Leukemia, Chronic Phase |
| AAPG | Imatinib, Dasatinib or Nilotinib | Chronic Myeloid Leukemia, Chronic Phase |
| AAPG | Palbociclib | Breast Cancer |
| AAPG | APG-2575 + DRd | Multiple Myeloma |
| AAPG | APG-2575+ Pd | Multiple Myeloma |
| AAPG | Rd | Multiple Myeloma |
| ABBV | Bevacizumab | Metastatic Colorectal Cancer |
| ABBV | Budigalimab | Non Small Cell Lung Carcinoma |
| ABBV | ABBV-706 | Small Cell Lung Cancer |
| ABBV | Lurbinectedin | Small Cell Lung Cancer |
| ABBV | Atezolizumab | Small Cell Lung Cancer |
| ABBV | Carboplatin | Small Cell Lung Cancer |
| ABBV | Pirtobrutinib | Mantle Cell Lymphoma |
| ABBV | Rituximab | Mantle Cell Lymphoma |
| ABBV | Cisplatin | Head and Neck Squamous Cell Carcinoma |
| ABBV | Pembrolizumab | Head and Neck Squamous Cell Carcinoma |
| ABBV | Pemetrexed | Non Small Cell Lung Carcinoma |
| ABBV | Fluorouracil | Metastatic Colorectal Cancer |
| ABBV | Leucovorin | Metastatic Colorectal Cancer |
| ABBV | Panitumumab | Metastatic Colorectal Cancer |
| ABBV | Oxaliplatin | Metastatic Colorectal Cancer |
| ABBV | Etoposide | Small Cell Lung Cancer |
| ABBV | Dexamethasone | Multiple Myeloma |
| ABBV | Daratumumab | Multiple Myeloma |
Phase 1 oncology (cancer) programs (991)
| Ticker | Drug | Indication |
|---|---|---|
| AAPG | Decitabine | Advanced Chronic Myeloid Leukemia |
| AAPG | Listaftoclax | Advanced Chronic Myeloid Leukemia |
| AAPG | APG-2449 | Advanced Solid Cancer |
| AAPG | PLD | Platinum-resistant Recurrent Ovarian Cancer |
| AAPG | APG -2449 | Platinum-resistant Recurrent Ovarian Cancer |
| AAPG | Ascentage Pharma HQP1351 bioavailable in | Leukemia, Myeloid, Chronic |
| AAPG | Osimertinib Mesylate Tablets | EGFR Positive Non-small Cell Lung Cancer |
| ABBV | Selinexor | Diffuse Large B-cell Lymphoma |
| ABBV | Daunorubicin | Acute Myeloid Leukemia |
| ABBV | ABBV-101 | Hematologic Cancer |
| ACET | ADI-270 | Clear Cell Renal Cell Carcinoma |
| ACHV | Custirsen, paclitaxel and carboplatin | Cancer |
| ACHV | SN2310 Injectable Emulsion | Breast Neoplasms |
| ACOG | [14C]Zorifertinib Oral Formulation | EGFR Mutant Advanced Non-small Cell Lung Cancer |
| ACOG | Zorifertinib and Osimertinib Combination | Patients With Advanced Non-small Cell Lung Cancer |
| ACOG | [211At]NaAt | DTC - Differentiated Thyroid Cancer |
| ACRS | Zunsemetinib | Metastatic Pancreatic Ductal Adenocarcinoma |
| ACRS | mFOLFIRINOX | Metastatic Pancreatic Ductal Adenocarcinoma |
| ACRS | ATI-2231 | Advanced Solid Tumor |
| ACTU | Chemotherapy | Pancreatic Adenocarcinoma |
| ACTU | Topotecan | Refractory Cancer |
| ACTU | Cyclophosphamide | Refractory Cancer |
| ACTU | Temozolomide | Refractory Cancer |
| ADAG | ADG206 | Advanced/Metastatic Solid Tumors |
| ADAG | anti PD1 drug | Advanced/Metastatic Solid Tumors |
| ADAG | ADG116 | Advanced/Metastatic Solid Tumors |
| ADCT | Loncastuximab tesirine and rituximab (Lo | Central Nervous System Lymphoma |
| ADCT | Mosunetuzumab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Glofitamab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Polatuzumab Vedotin | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Obinutuzumab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Loncastuximab Tesirine and Acalabrutinib | Chronic Lymphocytic Leukemia |
| ADCT | ADCT-901 | Advanced Solid Tumors |
| ADCT | ADCT-601 | Advanced Solid Tumors |
| ADCT | Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma |
| ADCT | Melphalan | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Carmustine | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Cytarabine | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Loncastuximab Tesirine and Durvalumab | Diffuse Large B-Cell Lymphoma |
| ADCT | ADCT-402 | Acute Lymphoblastic Leukemia |
Track cancer catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a cancer watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →